Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial | Zendy

Édouard Louis | Zendy; Robert Löfberg | Zendy; Walter Reinisch | Zendy; Anne Camez | Zendy; Mei Yang | Zendy; Paul F. Pollack | Zendy; Naijun Chen | Zendy; Jingdong Chao | Zendy; Parvez Mulani | Zendy

Open Access

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial

Author(s) -

Édouard Louis,

Robert Löfberg,

Walter Reinisch,

Anne Camez,

Mei Yang,

Paul F. Pollack,

Naijun Chen,

Jingdong Chao,

Parvez Mulani

Publication year - 2012

Publication title -

journal of crohn s and colitis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.277

H-Index - 80

eISSN - 1876-4479

pISSN - 1873-9946

DOI - 10.1016/j.crohns.2012.02.017

Subject(s) - medicine , adalimumab , infliximab , crohn's disease , quality of life (healthcare) , work productivity , disease , inflammatory bowel disease , population , physical therapy , intensive care medicine , productivity , nursing , economics , macroeconomics , environmental health

Crohn's disease negatively affects patients' quality of life and ability to work. We investigated the impact of adalimumab on work productivity, daily activities, and quality of life in an open-label trial (N=945). The population comprised both infliximab-naïve and -exposed patients, including infliximab primary non-responders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research